PTGXPROTAGONIST THERAPEUTICS INC
CUSIP 74366E102 · common stock
6 tracked investors held PROTAGONIST THERAPEUTICS INC (PTGX) at the end of Q3 2026, worth $290M in total. The largest holder was Adar1 Capital Management, with 5.7% of its portfolio. Stanley Druckenmiller sold out of its position this quarter.
Holders · Q3 2026
6
New holders
0
Value held
$290M
Quarter-end price (est.)
$140.89
Investors holding PTGX · Q3 2026
| Investor | Weight | Shares | Value | Change |
|---|---|---|---|---|
| Adar1 Capital Management ADAR1 Capital Management, LLC | 5.71% | 951,403 | $134M | REDUCE-1.0% |
| Perceptive Advisors Perceptive Advisors LLC | 2.05% | 836,579 | $117.9M | REDUCE-14.8% |
| Ken Fisher Fisher Asset Management, LLC | 0.01% | 168,373 | $23.7M | REDUCE-1.3% |
| Joel Greenblatt Gotham Asset Management, LLC | 0.02% | 65,298 | $9.2M | ADD+249.9% |
| Polen Capital Management Polen Capital Management LLC | 0.03% | 20,963 | $3M | REDUCE-7.5% |
| Ron Baron BAMCO Inc. (Baron Capital) | 0.00% | 16,000 | $2.3M | HOLD |
Sold out this quarter
| Investor | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| Stanley Druckenmiller | 0.49% | 208,900 | $25.6M | EXIT |